Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519760-40-00

Acronym

TEBE-RT

Enrollment

Registered

2025-07-21

Start date

2025-10-14

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic uveal melanoma HLA A*02:01 positive

Brief summary

The primary endpoint is the progression-free survival, which will be calculated from the day of treatment initiation to the progression. The PFS rate at 6 months will be evaluated

Detailed description

disease control rate at first tumor assessment, objective response rate, overall survival, treatment duration, time to subsequent treatment initiation, safety, evaluation of patients’ circulating immune profile and inflammatory microenvironment of uveal melanoma and correlation with PFS, analysis of ctDNA and correlation with PFS and OS

Interventions

DRUGTEBENTAFUSP

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the progression-free survival, which will be calculated from the day of treatment initiation to the progression. The PFS rate at 6 months will be evaluated	—

Secondary

Measure	Time frame
disease control rate at first tumor assessment, objective response rate, overall survival, treatment duration, time to subsequent treatment initiation, safety, evaluation of patients’ circulating immune profile and inflammatory microenvironment of uveal melanoma and correlation with PFS, analysis of ctDNA and correlation with PFS and OS	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026